biotech.today

Details

  • ●Modalities: small molecules, gene therapy (selective)
  • ●Therapeutic areas: metabolic disease, neurodegeneration
  • ●Key targets:
  • ●Indications: NAFLD/NASH, ALS
  • ●Funding: $1.05B

Partners & investors

  • BMS· Investor

Key considerations

  • ●AI tools in use: Insitro Platform
  • ●$543M Series C (2021)
  • ●Gilead $1.05B collaboration
  • ●BMS oncology partnership
Get live updates on Insitro’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Daphne Koller

Founder & CEO

machine-learningdrug-discoverygenomics
Visit website →LinkedIn →